Skip to main content
SPHDF logo

Santhera Pharmaceuticals Holding AG (SPHDF) Stock Price & Analysis

Santhera Pharmaceuticals Holding AG (SPHDF) — price $18.30 (0.00%), as of the Nov 18, 2026 trading session; market cap $280M.

Educational signal · not a buy or sell recommendation · How to read this

$18.30 $0.00 (0.00%) Market Cap $280M

Santhera Pharmaceuticals Holding AG · SPHDF

Santhera Pharmaceuticals Holding AG is a specialized drug developer focused on therapies for rare neuromuscular and lung conditions, operating across the European Union and globally. The company's pipeline features vamorolone for Duchenne muscular dystrophy and lonodelestat for cystic fibrosis, alongside an approved licensed medication, Raxone.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PLX · Protalix BioTherapeutics, Inc. · 90 /100
  • CGEN · Compugen Ltd. · 69 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$18.30
Change on the day0.00%
52-week range$13.35 – $23.25
Market capitalisation$280M—
Shares traded on the day100

Price & events

Other perspectives

Council score for Santhera Pharmaceuticals Holding AG (SPHDF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Strong
Gross Margin Weak

Read on: Jun 14, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jun 14, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Santhera Pharmaceuticals Holding AG (SPHDF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Santhera Pharmaceuticals Holding AG (SPHDF) is the company analyzed here. It employs 78 people and is led by Orlando Oliveira. In Q2 FY2026 it reported revenue of CHF 48M and net income of -CHF 21M. The market values it at $280M.

2 · Latest results

What do the latest results show for Santhera Pharmaceuticals Holding AG (SPHDF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CHF 48M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CHF 48M-CHF 21M-CHF 1.49 (diluted)
Q4 FY2025CHF 53M-CHF 10M-CHF 0.78 (diluted)
Q2 FY2025CHF 24M-CHF 39M-CHF 3.04 (diluted)
Q4 FY2024CHF 25M-CHF 27M-CHF 2.34 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Santhera Pharmaceuticals Holding AG (SPHDF)?

Short answer · as of

The distress and quality screens read Altman Z -4.82 · Piotroski F 6. Trailing ratios: ROE 355.0% · ROA -21.7% · current ratio 1.73 · earnings yield -15.2% · free-cash-flow yield 0.3%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SPHDF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SPHDF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Santhera Pharmaceuticals Holding AG (SPHDF)?

Read these with our analysis →

Santhera Pharmaceuticals Holding AG Stock: Key Questions Answered

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

Is SPHDF a good stock to buy?

Stock Expert AI does not rate SPHDF buy, sell or hold. Santhera Pharmaceuticals Holding AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SPHDF stock price today?

The last price recorded for Santhera Pharmaceuticals Holding AG (SPHDF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for SPHDF?

Evaluate SPHDF on fundamentals, analyst consensus, and risk factors. Primary focus on developing therapies for rare neuromuscular and lung conditions, addressing areas with high unmet medical needs. Not financial advice.

How frequently does SPHDF data refresh on this page?

SPHDF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SPHDF's recent stock price performance?

Santhera Pharmaceuticals Holding AG (SPHDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Niche focus on rare neuromuscular and lung conditions addresses significant unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SPHDF overvalued or undervalued right now?

Santhera Pharmaceuticals Holding AG (SPHDF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research SPHDF before investing?

Before investing in Santhera Pharmaceuticals Holding AG (SPHDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding SPHDF to a portfolio?

Key strength of Santhera Pharmaceuticals Holding AG (SPHDF): Niche focus on rare neuromuscular and lung conditions addresses significant unmet medical needs. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.